Spruce Point: Dexcom Could Fall 45-60%

Loading...
Loading...

DexCom, Inc. DXCM shares are trading lower after a new report from Spruce Point Capital argued the stock could fall 45-60 percent.

The San Diego-based company manufacturers continuous glucose monitoring systems for diabetic patients.

Until now, the company’s G-Series model has been considered the gold standard, while its competitor Abbott Laboratories ABT offered a cheaper, user-friendly alternative with the FreeStyle Libre, according to Spruce Point. 

Abbott is set to release the Libre 2 in the U.S. and Spruce Point said the launch will close most if not all technological gaps with Dexcom’s G-Series.

This move will put heavy pressure on Dexcom profits with little downside to Abbott's margin, the report said.

“The Street believes that the downmarket Libre is not a serious threat to Dexcom’s market, but the LIbre has taken [greater than 70 percent] incremental share of the U.S. Type 1 market and [greater than 95 percent] incremental share of the U.S. Type 2 market since first being released in the U.S." 

Dexcom has few avenues for near-term patient growth and will be effectively locked out of the Type 2 market until it releases a cheaper, downmarket CGM similar to the Libre, according to Spruce Point. 

“We see 45-60-percent near-term downside in DXCM shares after disappointing sales growth and a multiple re-rating, and even more potential future downside on long-term price pressure." 

DexCom shares were down 3.13 percent at $141.59 at the time of publication Thursday. 

Related Links:

The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs

Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

Photo courtesy of Dexcom. 

Loading...
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorShort SellersShort IdeasHealth CareAnalyst RatingsTrading IdeasGeneralG-SeriesLibre 2Spruce Point CapitalSprucepoint Capital
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...